Full Logo - OKYO .jpg
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
March 21, 2024 07:00 ET | OKYO Pharma LTD
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
1
Garry Lowenthal Joins PetVivo Holdings, Inc. as the Chief Financial Officer
March 11, 2024 08:00 ET | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, March 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
Logo.jpg
PetVivo Holdings, Inc. Commences Trading on Upstream Under PETV
March 05, 2024 08:00 ET | PetVivo Holdings, Inc.
PetVivo Dual Lists on Upstream's Global Securities Trading App MINNEAPOLIS, MN, March 05, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging...
Logo.jpg
Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California
February 29, 2024 08:00 ET | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the...
Logo.jpg
PetVivo Holdings, Inc. Approved to Dual List on Upstream
February 27, 2024 08:00 ET | PetVivo Holdings, Inc.
Trading to begin on March 5, 2024 under “PETV”, all shareholders to receive commemorative NFT MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW)...
Logo.jpg
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE WESTERN VETERINARY CONFERENCE IN LAS VEGAS, NEVADA
February 13, 2024 08:00 ET | PetVivo Holdings, Inc.
MINNEAPOLIS, Feb. 13, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative...
Logo.jpg
PetVivo Reports Third Quarter of Fiscal 2024 Financial Results
February 12, 2024 16:00 ET | PetVivo Holdings, Inc.
Conference call begins at 4:00 p.m. Central time today EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the...
Full Logo - OKYO .jpg
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
February 09, 2024 07:00 ET | OKYO Pharma LTD
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe...
Logo.jpg
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy
February 07, 2024 08:00 ET | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the...
Logo.jpg
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2024
February 06, 2024 12:37 ET | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 06, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical...